Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has completed the expansion of its research and development laboratory in Lund, Sweden. The expansion of a third laboratory will provide us separate laboratories for LinkGut sample analysis, microbial therapeutic research, and prebiotic ingredient development. The laboratory expansion will also provide additional office space that will allow the Company to bring together all personnel based in Lund into one office and laboratory area. The expansion allows Carbiotix to ramp up research and development activities across all modulator classes and for personnel to work more effectively.
Kristofer Cook, CEO of Carbiotix, comments
"I am very happy to announce that Carbiotix has completed the expansion of its research and development laboratory in Lund. The addition of a third laboratory unit will allow the Company to operate separate labs for LinkGut sample analysis, microbial therapeutic research and prebiotic ingredient development. This is especially important now that we are ramping up research and development efforts with regards to new prebiotics, medical foods and therapeutic co-treatments. The laboratory expansion will also allow us to consolidate all personnel into one office and laboratory area, thus improving the working environment and allowing for more interaction between employees.
A decision to expand the research and development laboratory was made at the end of last year and the renovations have taken roughly one month after the laboratory and office space became available at the beginning of April. This expansion should provide enough space for all Company activities and personnel for the next 3 years."
Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.